You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

recurrent ovarian epithelial cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A Prospective, Randomized Controlled Study of Cyclophosphamide,

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Shijiazhuang, Hebei, China
    Hebei
Aug 20, 2023

Safety of Niraparib in Korean Primary and Recurrent Epithelial

Completed
  • Epithelial Ovarian Cancer
  • Seoul, Korea, Republic of
    Department of Obstetrics and Gynecology, University of Ulsan Col
Oct 11, 2023

Ovarian Cancer Trial (Gleolan)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Mar 27, 2023

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

Participation Patterns Among Recurrent Ovarian Cancer Patients

Not yet recruiting
  • Recurrent Ovarian Cancer
    • San Francisco, California
      Power Life Sciences
    Sep 30, 2023

    Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer Trial in Duarte, Pasadena

    Active, not recruiting
    • Fallopian Tube Cancer
    • +2 more
    • Duarte, California
    • +1 more
    Mar 17, 2022

    Ovarian Cancer Trial in Seoul (Cellgram-DC)

    Terminated
    • Ovarian Cancer
    • Cellgram-DC
    • Seoul, Korea, Republic of
      Asan medical center
    Dec 29, 2022

    Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

    Not yet recruiting
    • Ovarian Carcinoma
    • Sacituzumab govitecan
    • New Haven, Connecticut
      Smilow Cancer Hospital at Yale New Haven
    Aug 31, 2023

    Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • Pittsburgh, Pennsylvania
      Magee-Womens Research Institute / UPMC Magee Womens Hospital
    Jul 3, 2023

    Recurrent Ovarian Cancer Trial (DOXIL, Withaferin A, Ashwagandha)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • (no location specified)
    Jan 27, 2023

    Ovarian Cancer Trial in Houston (Nivolumab, Etigilimab)

    Not yet recruiting
    • Ovarian Cancer
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 27, 2023

    Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer Trial in Denmark, Norway, Sweden (KAND567, Carboplatin)

    Recruiting
    • Epithelial Ovarian Cancer
    • +2 more
    • Odense, Denmark
    • +3 more
    Oct 16, 2023

    Platinum-resistant Ovarian Cancer Trial in Shanghai (Oral Topotecan Combined With Anlotinib)

    Not yet recruiting
    • Platinum-resistant Ovarian Cancer
    • Oral Topotecan Combined With Anlotinib
    • Shanghai, China
      Xinhua Hospital Affiliated to Shanghai Jiaotong University Schoo
    Feb 12, 2023

    Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer Trial (AsiDNA, Olaparib)

    Not yet recruiting
    • Metastatic Castration-resistant Prostate Cancer
    • +2 more
    • (no location specified)
    Jan 17, 2023

    Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

    Recruiting
    • Ovarian Cancer
    • NKG2D CAR-NK
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Mar 26, 2023

    Ovarian Cancer Recurrent Trial in Beijing (IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin)

    Recruiting
    • Ovarian Cancer Recurrent
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Science and Peking Un
    Aug 23, 2023

    Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

    Not yet recruiting
    • Ovarian Cancer
    • +3 more
    • Beijing, Beijing, China
      Lingying Wu
    Aug 22, 2023

    Ovarian Cancer Trial in Maywood (Minoxidil)

    Recruiting
    • Ovarian Cancer
    • Maywood, Illinois
      Loyola University Medical Center
    Jun 23, 2022

    Ovarian Cancer, Epithelial Trial in Nanjing (Envafolimab, Lenvatinib, VP-16)

    Not yet recruiting
    • Ovarian Cancer, Epithelial
    • Nanjing, Jiangsu, China
      Zhongda Hospital
    Jun 13, 2022

    Ovarian Cancer Recurrent Trial in Birmingham (M4344+Niraparib)

    Not yet recruiting
    • Ovarian Cancer Recurrent
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Jan 5, 2023

    Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • Fuzuloparib Combination with Bevacizumab
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Cente
    Apr 14, 2023

    Epithelial Ovarian Cancer Trial in Goyang-si (HIPEC)

    Recruiting
    • Epithelial Ovarian Cancer
    • HIPEC
    • Goyang-si, Gyeonggi-do, Korea, Republic of
      Myong Cheol Lim
    Apr 23, 2022

    Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

    Recruiting
    • Recurrent Ovarian Cancer
    • +6 more
    • Durham, North Carolina
    • +2 more
    Jul 26, 2022

    Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion Trial in United States (metformin HCl, , Chemotherapy)

    Suspended
    • Brenner Tumor
    • +27 more
    • metformin hydrochloride
    • +2 more
    • Birmingham, Alabama
    • +9 more
    May 16, 2022

    Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New Haven, Baltimore (Ixabepilone,

    Active, not recruiting
    • Epithelial Ovarian Cancer
    • +2 more
    • New Haven, Connecticut
    • +1 more
    Jan 11, 2023